Michael J. Mauro, MD, provides a summary of the SIMPLICITY trial. For more information, tools, resources and CE activities please…
Browsing: Acute Lymphoblastic Leukemia
Stuart L. Goldberg, MD provides CML meeting highlights live from the 2015 ASCO Annual Meeting that significantly impact practice. For…
Dr. Karen Seiter discusses the efficacy and safety considerations in using ponatinib. For more information, tools, resources and CE activities…
Dr. Karen Seiter discusses the most common reasons for treatment failur For more information, tools, resources and CE activities please…
Dr. Karen Seiter discusses using second-generation TKIs as a first-line approach. For more information, tools, resources and CE activities please…
Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients. For more information, tools, resources…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston,…
Is there a role for second-line therapy in advanced pancreatic cancer? For more information, tools, resources and CE activities please…
Dr. Koushik Das discusses the type of patients that would benefit from pancreatic cancer screening. For more information, tools, resources…
Dr. Koushik Das discusses screening tests and predictive biomarkers for pancreatic cancer. For more information, tools, resources and CE activities…
Dr. Jill Lacy discusses radiotherapy in the treatment of pancreatic cancer, how its role is evolving in specific settings, and…
Dr. Jill Lacy discusses the development of immune therapies for pancreas cancer, the progress that is being made, and provides…
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the…
At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic,…
At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany,…
At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany,…
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the ClÃnica Universidad de…
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St…
Breast Cancer Index (BCI) is a molecular, gene expression-based test uniquely positioned to identify patients best suited for extended endocrine…
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, MarÃa-Victoria Mateos, MD, PhD, of the University Hospital of…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université…
Patrick I. Borgen, M.D, of the Brooklyn Breast Cancer Center talks about reducing opioids in breast cancer surgery using Bupivacaine
Charles L. Loprinzi, MD, of the Mayo Clinic discusses the management of Hot Flashes using SSRI, Gabapentin, Venlafaxine in patients…
Charles L. Loprinzi, MD, of the Mayo Clinic reviews how Olanzapine Decreases Nausea and Vomiting in Patients With Esophageal, Head…
Charles L. Loprinzi, MD, of the Mayo Clinic talks about scrambler therapy for the treatment of chemotherapy- induced peripheral neuropathy
Hope S. Rugo, MD of the UCSF Medical Center talks about the I-SPY 2 Trial and MK-2206 which shows benefit…
Hope S. Rugo, MD of the UCSF Medical Center discusses numerous trials associated with checkpoint inhibitors in triple negative breast…
Hope S. Rugo, MD of the UCSF Medical Center discusses the state of CDK 4/6 Inhibitors for Patients with HR+/HER-…
Hope S. Rugo, MD of the UCSF Medical Center discusses scalp cooling system which prevented significant hair loss in 70.3%…
Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that…
Maha Hussain, MD of University of Michigan Comprehensive Cancer Center discusses Phase II Androgen Deprivation Therapy with Palbociclib
Maha Hussain, MD of the University of Michigan Comprehensive Cancer Center discusses ETS Gene Fusions as a Predictive Biomarker in…
Robert J. Mayer, MD of Dana-Farber Cancer Institute discusses the results of the TAS-102 Trial for Refractory Metastatic Colorectal Cancer
HOWARD A. “SKIP” BURRIS, III, MD of Sarah Canon discusses the PD-1 Benefit in Progression Free Survival for Non-Small Cell…
Nicholas J. Vogelzang, MD or the University of Illinois discusses the expanded access of Radium-223 for prostate cancer patients
Nicholas J. Vogelzang, MD of the University of Illinois discusses second line bladder cancer and PD-L1 antibody
Nicholas J. Vogelzang, MD of the University of Illinois discusses a new trial Sunitinib v. PD-L1 with Bevacizumab
Nicholas J. Vogelzang, MD of the University of Illinois discusses the state of kidney cancer June 2015
Jason Luke, MD of the University of Chicago discusses Phase III Trial Pembrolizumab is Better Than Ipilimumab for Advanced Melanoma
Jason Luke, MD of the University of Chicago discusses gene expression profiling and immune signatures
Jason Luke, MD, of the University of Chicago discusses the Ipilimumab and Nivolumab Combination Study
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved…
The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result…
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3…